急性白血病bcl-2、bax测定的临床意义

Clinical significance of detection of bcl-2 and bax in acute leukemia

目的探讨急性白血病(AL)患者bcl-2、bax的表达与临床治疗及预后的关系。方法采用S-P免疫组化法检测AL患者骨髓单个核细胞(BMMNC)上bcl-2及bax的表达水平,行AL疗效分析。结果急性髓细胞白血病(AML)和急性淋巴细胞白血病(ALL)患者bcl-2表达分别为(46.12±27.29)%和(57.94±32.19)%,均明显高于正常对照组(15.4±5.64)%(P<0.01),AML与ALL间bcl-2表达差异无统计学意义(P>0.05);49例AL临床治疗有效组bcl-2表达为(36.81±30.35)%,无效组为(56.36±26.78)%,无效组高于有效组(P<0.05)。各组间bax差异均无统计学意义(P>0.05)。结论bcl-2水平对判断AL疗效和预后有重要价值。

[Objective] To detect the expression level of bcl-2,bax in acute leukemia （AL）,offer the experimental basis to judge the clinical curative effect and prognosis of AL. [Methods ] S-P immunohistochemistry was used in detection of the expression of bcl-2 and bax in bone marrow mononuclear cells （BMMNC） from 49 cases of AL, and analyzed the clinical curative effect of AL. [Results] The bcl-2 expression of acute myeloid leukemia （AML） and acute lymphocytic leukemia （ALL） was （46.12±27.29）% and （57.94±32.19）% respectirely, and both markedly higher than that of control （15.4±5.64）% （P〈0. 01）. The difference of bcl-2 and bax between AML and ALL had no statistical significance. ②16 cases were effective and 33 cases were invalid in 49 cases of AL,the level of bcl-2 of the effective cases was higher than that of the invalid cases. There are no difference of bax between them （P〉0. 05）. [Conclusion] The level of bcl-2 has significance for determining the therapy efficacy and prognosis of AL and bax doesn＇t.